Literature DB >> 2446602

Design, synthesis and bioassays of antagonists of LHRH which have high antiovulatory activity and release negligible histamine.

A Ljungqvist1, D M Feng, P F Tang, M Kubota, T Okamoto, Y W Zhang, C Y Bowers, W A Hook, K Folkers.   

Abstract

Potent antagonists of the luteinizing hormone releasing hormone have been achieved which release negligible histamine. [N-Ac-D-2-Nal1, D-pClPhe2, D-3-Pal3, NicLys5, D-NicLys6, ILys8, D-Ala10]-LHRH showed 100%AOA/1 microgram and 36%/0. 5 micrograms; ED50 greater than 300. [N-Ac-D-2-Nal1,D-pClPhe2,D-3-Pal3, PicLys5, D-PicLys6, ILys8, D-Ala10]-LHRH showed 100% AOA/0.5 micrograms and 40%/0.25 micrograms; ED50, 93 +/- 11, and is the most potent of 52 new peptides. These antagonists feature designs with weakly basic acylated D-Lys6, notably D-NicLys6 and D-PicLys6 and alkylated Lys8 or Orn8, e.g., ILys8 and IOrn8, and NicLys5 and PicLys5. Concepts included balanced overall basicity, superiority of ILys8 and IOrn8 which are sequence dependent and sensitivity of positions 5 and 6 for potency.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2446602     DOI: 10.1016/0006-291x(87)90953-3

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  8 in total

1.  Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.

Authors:  Manoj P Samant; Doley J Hong; Glenn Croston; Catherine Rivier; Jean Rivier
Journal:  J Med Chem       Date:  2006-06-15       Impact factor: 7.446

2.  Antide and related antagonists of luteinizing hormone release with long action and oral activity.

Authors:  A Ljungqvist; D M Feng; W Hook; Z X Shen; C Bowers; K Folkers
Journal:  Proc Natl Acad Sci U S A       Date:  1988-11       Impact factor: 11.205

3.  Structure-activity relationship studies of gonadotropin-releasing hormone antagonists containing S-aryl/alkyl norcysteines and their oxidized derivatives.

Authors:  Manoj P Samant; Richard White; Doley J Hong; Glenn Croston; P Michael Conn; Jo Ann Janovick; Jean Rivier
Journal:  J Med Chem       Date:  2007-04-03       Impact factor: 7.446

4.  Spantide II, an effective tachykinin antagonist having high potency and negligible neurotoxicity.

Authors:  K Folkers; D M Feng; N Asano; R Håkanson; Z Weisenfeld-Hallin; S Leander
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

5.  Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II.

Authors:  Manoj P Samant; Jozsef Gulyas; Doley J Hong; Glenn Croston; Catherine Rivier; Jean Rivier
Journal:  J Med Chem       Date:  2005-07-28       Impact factor: 7.446

6.  Spantide III, a superior tachykinin antagonist with high potency and negligible neurotoxicity.

Authors:  K Folkers; R Hakanson; D M Feng; J C Xu; A Janecka; Z Y Wang
Journal:  Amino Acids       Date:  1993-06       Impact factor: 3.520

7.  The structural features of effective antagonists of the luteinizing hormone releasing hormone.

Authors:  A Janecka; T Janecki; C Bowers; K Folkers
Journal:  Amino Acids       Date:  1994-06       Impact factor: 3.520

8.  Antide B, an antagonist of LHRH with cis-3-(4-pyrazinylcarbonylaminocyclohexyl)alanine in position 5.

Authors:  A Janecka; T Janecki; C Bowers; K Folkers
Journal:  Amino Acids       Date:  1995-03       Impact factor: 3.520

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.